Cancer

Robert H. Bradbury (auth.), Robert H. Bradbury (eds.)9783540331193, 3-540-33119-0

The last decade has seen a dramatic shift in anticancer drug research towards agents that aim to selectively target key regulatory and signaling processes known to drive tumorigenesis. A number of these newer agents have now been introduced into clinical practice. This volume reviews advances in cancer chemotherapy research over the last 10 years and will be of interest to scientists engaged in drug research in the pharmaceutical industry, biotechnology and startup companies, academia and government institutions. Chapters written by leading experts in their field reflect a range of current medicinal chemistry approaches to small molecule drugs, including anti-hormonal therapy, growth factor inhibition, survival signaling, cell cycle inhibition, anti-angiogenics and anti-nvasives. Each chapter aims to cover the drug target and biological rationale, chemotypes, clinical status and future prospects in this rapidly developing area of drug research.

---

Table of contents :
Front Matter….Pages I-XIV
Overview….Pages 1-17
Anti-hormone Therapy: Principles of Endocrine Therapy of Cancer….Pages 19-82
Inhibition of Growth Factor Signaling by Small-Molecule Inhibitors of ErbB, Raf, and MEK….Pages 83-132
Farnesyl Protein Transferase Inhibitors: Medicinal Chemistry, Molecular Mechanisms, and Progress in the Clinic….Pages 133-168
Survival Signaling….Pages 169-206
Progress in the Development of Agents to Control the Cell Cycle….Pages 207-291
HDAC Inhibition in Cancer Therapy: An Increasingly Intriguing Tale of Chemistry, Biology and Clinical Benefit….Pages 293-331
Development of Angiogenesis Inhibitors to Vascular Endothelial Growth Factor Receptor 2 for Cancer Therapy….Pages 333-382
Novel Small-Molecule Inhibitors of Src Kinase for Cancer Therapy….Pages 383-405
Bcr-Abl Kinase Inhibitors….Pages 407-444
Back Matter….Pages 445-451